Evidence map›Paper›PMID 33650690›Full record

ArticleVox sanguinis2021

Anti-A and SARS-CoV-2: an intriguing association.

Valeria de Freitas Dutra, Carolina Bonet-Bub, Ana Paula H Yokoyama, Ruth Achkar, Rafael Rahal Guaragna Machado, Murilo Assunção, Gabriela Candelária, Camila Pereira Soares, Roberta Maria Fachini, Rita Fontão-Wendel and 11 more

Open access · bronzeAbstract read
In one paragraph

Article in Vox sanguinis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 3 institutions in 1 country.

Valeria de Freitas DutraHospital Israelita Albert Einstein, São Paulo, Brazil.
Carolina Bonet-BubHospital Israelita Albert Einstein, São Paulo, Brazil.ORCID https://orcid.org/0000-0001-5103-4970
Ana Paula H YokoyamaHospital Israelita Albert Einstein, São Paulo, Brazil.
Ruth AchkarHospital Sírio Libanês, São Paulo, Brazil.
Rafael Rahal Guaragna MachadoDepartment of Microbiology, Institute of Biomedical Sciences, University of Sao Paulo, São Paulo, Brazil.
Murilo AssunçãoHospital Israelita Albert Einstein, São Paulo, Brazil.
Gabriela CandeláriaHospital Sírio Libanês, São Paulo, Brazil.
Camila Pereira SoaresDepartment of Microbiology, Institute of Biomedical Sciences, University of Sao Paulo, São Paulo, Brazil.
Roberta Maria FachiniHospital Sírio Libanês, São Paulo, Brazil.
Rita Fontão-WendelHospital Sírio Libanês, São Paulo, Brazil.
Nelson HamerschlakHospital Israelita Albert Einstein, São Paulo, Brazil.
Luiz Fernando Lima ReisHospital Sírio Libanês, São Paulo, Brazil.
Danielle Bastos AraujoHospital Israelita Albert Einstein, São Paulo, Brazil.
Victor NudelmanHospital Israelita Albert Einstein, São Paulo, Brazil.
Joao R R PinhoHospital Israelita Albert Einstein, São Paulo, Brazil.
Luiz V RizzoHospital Israelita Albert Einstein, São Paulo, Brazil.
Araci M SakashitaHospital Israelita Albert Einstein, São Paulo, Brazil.
Patrícia ScuracchioHospital Sírio Libanês, São Paulo, Brazil.
Edison Luiz DurigonDepartment of Microbiology, Institute of Biomedical Sciences, University of Sao Paulo, São Paulo, Brazil.
Silvano WendelHospital Sírio Libanês, São Paulo, Brazil.
Jose M KutnerHospital Israelita Albert Einstein, São Paulo, Brazil.ORCID https://orcid.org/0000-0003-3784-6731
Hospital Israelita Albert Einstein · BRHospital Sírio-Libanês · BRUniversidade de São Paulo · BR

Funding

Coordenação de Aperfeiçoamento Pessoal de Nível Superior - CAPES 88 887.131387/2016-00Fundação de Amparo à Pesquisa do Estado de São Paulo 2016/20045-7Fundação de Amparo à Pesquisa do Estado de São Paulo 2020/06409-1Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP), projects no 2017/24769-2 (RRGM), 2018/23680-0 (CPS) and 2016/20045-7 (ELD). Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), project no 88887.131387/2016-00 (DBA).Todos Pela Saúde - Fundação Itaú para Educação e Cultura
6 · The paper itself

Abstract

backgroundBlood groups and anti-A isohemagglutinin may be involved in susceptibility to SARS-CoV-2 infection. MATERIALS AND

methodsWe retrospectively studied 268 COVID-19 convalescent plasma donors and 162 COVID-19 inpatients (total 430 subjects, confirmed by RT-PCR) and 2,212 healthy volunteer first-time blood donors as a control group. These were further divided into two groups: those with anti-A (blood types O and B) and those without it (types A and AB). Titres of nucleoproteins, and neutralizing SARS-CoV-2 antibody were measured in the convalescent plasma donors and inpatients. Multivariate logistic regression and non-parametric tests were applied.

resultsPersons having types O or B showed less infection prevalence than those of types A or AB (OR = 0·62, 95% CI 0·50-0·78; P < 0·001), but there was no difference when COVID-19 inpatients were analysed. Immunoglobulins M, G and A were lower in COVID-19 subjects of types O or B group than those of A or AB (0·16 vs. 0·19; P = 0·03, 2·11 vs. 2·55; P = 0·02, 0·23 vs. 0·32; P = 0·03, respectively).

conclusionIn this retrospective cohort, COVID-19 individuals were less likely to belong to blood types O and B, and also had lower SARS-CoV-2 antibody titres than A and AB individuals. COVID-19 severity did not associate with the blood groups.

Indexed as

ABO Blood-Group SystemAdultAntibodies, NeutralizingAntibodies, ViralCOVID-19COVID-19 SerotherapyHemagglutininsHumansImmunization, PassiveMaleMiddle AgedSARS-CoV-2ABO Blood-Group SystemAntibodies, NeutralizingAntibodies, ViralHemagglutininsABO groupsanti-ASARS-CoV-2

Identifiers

PMID33650690
PMCPMC8013368
OpenAlexW3134959149

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.